Comparison of Clinical Features and Outcomes Between HBV-related and Non-B Non-C Hepatocellular Carcinoma
Overview
Authors
Affiliations
Objective: To evaluate the difference between hepatitis B virus related hepatocellular carcinoma (HBV-HCC) and non-HBV non-HCV hepatocellular carcinoma (NBNC-HCC) patients based on clinical features and prognosis.
Methods: A total of 175 patients with HCC were enrolled. Patients' characteristics were extracted from medical records. Among them, 107 patients were positive for HBsAg and negative for HCV-Ab while 68 patients were negative for HBsAg and HCV-Ab.
Results: The patients in the NBNC-HCC group were significantly older than those in the HBV-HCC group ( = 0.045). Moreover, vascular invasion was found in 23.4% of HBV-HCC patients, which was significantly higher than that in the NBNC-HCC patients with 10.3% ( = 0.029). Kaplan-Meier analysis revealed that HBV-HCC patients had significantly worse outcomes in terms of overall survival ( = 0.036). Compared with the NBNC-HCC patients, the HBV-HCC patients had a significantly worse disease-free survival ( = 0.0018). The multivariate analysis results indicated that TNM stage (HR = 1.541, 95%CI 1.072-2.412, = 0.002) and HBV infection (HR = 1.087, 95%CI 1.012-1.655, = 0.042) were independent risk variables for overall survival. While vascular invasion (HR = 1.562, 95%CI 1.013-2.815, = 0.042) and HBV infection (HR = 1.650, 95%CI 1.017-2.676, = 0.037) were independent risk factors associated with disease-free survival.
Conclusion: Our data revealed that HBV-HCC is more common in young males with vascular invasion, while NBNC-HCC occurs mostly in elderly patients, and overall survival rate is significantly better than that of HBV-HCC. Our study therefore provides evidence that patients with HBV-HCC require closer follow-up due to their poor prognosis.
Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W Cancer Immunol Immunother. 2025; 74(2):69.
PMID: 39751879 PMC: 11699032. DOI: 10.1007/s00262-024-03917-w.
Chen X, Liu H, Pan D, Yao Z, Han Z, Qu P Technol Cancer Res Treat. 2024; 23:15330338241277695.
PMID: 39263703 PMC: 11406659. DOI: 10.1177/15330338241277695.
Zhang H, Ding J, Zhou Y Am J Transl Res. 2024; 16(6):2301-2309.
PMID: 39006275 PMC: 11236653. DOI: 10.62347/BDLO2786.
Zhu Y, Zhao Y, Ning Z, Deng Y, Li B, Sun Y Cell Commun Signal. 2024; 22(1):280.
PMID: 38773448 PMC: 11106961. DOI: 10.1186/s12964-024-01619-5.
Chen R, An Y, Xu M PLoS One. 2024; 19(3):e0298014.
PMID: 38547200 PMC: 10977706. DOI: 10.1371/journal.pone.0298014.